Skip to main content

Table 2 Gene-level summary P values associated with mammographic density change after quitting EPT use

From: Hormone metabolism pathway genes and mammographic density change after quitting estrogen and progestin combined hormone therapy in the California Teachers Study

Gene Number of SNPs genotyped Gene-level association P value *
AKR1C4 1 0.44
AR 6 0.39
ARSC 2 0.02
COMT 21 0.14
CYP11A 12 0.64
CYP19A1 2 0.80
CYP1A1/CYP1A2 5 0.97
CYP1B1 15 0.61
CYP21A2 2 0.13
CYP2C9 16 0.73
CYP3A4 3 0.46
ESR1 13 0.81
ESR2 22 0.68
HSD17B1 5 0.11
HSD17B2 24 >0.99
HSD17B4 24 0.49
HSD17B5/AKR1C3 38 0.85
HSD3B1 4 0.14
HSD3B2 10 0.97
PGR 32 0.81
SHBG 13 0.60
SLCO1B1 (SLC21A6) 38 0.04
SRD5A1 24 0.80
SULT1A1/SULT1A2 6 0.26
SULT1E1 18 0.50
UGT1A8 43 0.99
UGT2B17 1 0.63
UGT2B7 5 0.52
  1. *Based on the adaptive rank truncated product (ARTP) statistics. EPT, estrogen and progestin combined therapy; SNP, single nucleotide polymorphisms.